Selenium can have cancer chemopreventive activity, although the mechanism of action has not been well defined. Selenazolidine-4-(R)-carboxylic acids (SCAs) were devised as prodrugs of l-selenocysteine, to provide selenium in a form and at a concentration commensurate with cancer chemopreventive activity. In the present study, a series of selenazolidines has been evaluated in the Salmonella typhimurium TA98 tester strain and all were found to possess antimutagenic activity. There was little difference between the seven selenazolidines in their effectiveness against either benzo 
Introduction
The antimutagenic property of selenium against chemical mutagens was first established [1] soon after [7, 8] . The selenite inhibition of B[a]P mutagenicity was attributed to its inhibitory effect on arylhydrocarbon hydroxylase (CYP1A) activity [5, 9] an action which decreases the bioactivating metabolism to mutagenic metabolites [4, 10] . In animals, selenite was an effective chemopreventive agent against 7,12-dimethylbenz[a]anthracene-induced mammary tumors in mice [11] [12] [13] and rats [14] but was not effective against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced mouse lung adenomas [15, 16] or azaserine-induced rat pancreatic and hepatic neoplasms [17] . Seleno-amino acids and their derivatives have also been investigated for cancer chemopreventive properties but were not effective against all classes of mutagens tested [13, 16, [18] [19] [20] [21] . In the only published antimutagenesis study for these organic selenium compounds, neither selenomethionine nor Se-methylselenocysteine were effective against 2-amino-3-methylimidazole [4, 5] quinoline [22] . Of the several organoselenium compounds that have been demonstrated to have tumor reducing activity against a variety of carcinogens in rats and mice [15, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] , to our knowledge no in vitro studies have been conducted to detect antimutagenic activity that could explain the observed anticarcinogenic effect.
An l-selenocysteine-prodrug approach was conceived as a way to supply the supranutritional selenium requirement necessary for cancer chemopreventive activity [35] without toxicity. As a prelude to in vivo evaluation, we pursued an investigation of antimutagenic properties of selenazolidine-4-(R)-carboxylic acid (SCA) and six 2-substituted derivatives (Fig. 1 ).
Materials and methods

Materials
The S. typhimurium TA98 bacterial strain was obtained from ATCC (Manassas, VA). B[a]P, acridine orange, 7-ethoxyresorufin, and NADPH were obtained from Sigma (St. Louis, MO). SCA was synthesized as described by Short et al. [36] , 2-oxoSCA and 2-methylSCA as described by Xie et al. [35] , and the four other 2-substituted selenazolidines were synthesized in a similar manner to 2-methylSCA except the appropriate carbonyl compound was substituted for acetaldehyde in the synthesis. S9 mix consisted of filter-sterilized NADPH (1.25 mM) and hepatic S9 fraction (4 mg protein/ml) prepared from male Sprague Dawley rats treated 3 days previously with a single dose (25 mg/kg, i.p. in corn oil) of Aroclor 1254.
Cytotoxicity
The cytotoxicity of the selenazolidines was determined under two exposure conditions; bacterial growth in complete broth [37] and bacterial colony growth on nutrient broth agar plates. In the former, S. typhimurium TA98 (1 × 10 6 cfu) were grown in Oxoid Nutrient Broth No. 2 in 96-well plates in the presence and absence of the selenazolidine compounds (10-200 M). After 15 h at 37
• C, the absorbance was determined at 570 nm. In the latter, with conditions that mimic those of the revertant mutagenesis/antimutagenesis assay described below, an appropriate dilution (10 −5 to 10 −7 ) of the overnight bacteria culture in LB medium, and selenazolidine (0, 10, 25, or 50 M), was mixed with 2.5 ml of warm 0.6% top agar (NaCl/agar), added to nutrient broth agar plates and incubated at 37
• C. The colony/plate evaluation was also performed following 30 min of incubation of the bacteria in the presence of 100 M acridine orange or 20 M B[a]P and S9 mix. Colonies on triplicate plates were counted after 24 h.
Mutagenicity and antimutagenicity
For assessing the mutagenic properties of the selenium compounds, 0.1 ml of a 16 h overnight S. typhimurium TA98 culture grown in LB medium was incubated with the selenium compound at 37
• C for 30 min in phosphate buffer (pH 7.4) in the presence and absence of S9 mix. The incubate (0.6 ml) was then added to top agar containing growth-initiating concentrations (50 M) of histidine and biotin, and poured on to minimal glucose agar plates. Revertant colonies were counted after incubation at 37
• C for 2 days. Background (spontaneous) revertant colonies were also counted, from incubations without selenazolidines. Revertant colonies seen with 20 M B[a]P incubated with S9 mix were performed alongside as a positive control.
For assessing the antimutagenic properties of the selenium compounds, 0.1 ml of the overnight LB culture used in the agar plate cytotoxicity evaluation (Section 2. 
Cytochrome P4501A inhibition
Rat hepatic S9 fraction used in the mutagenesis/ antimutagenesis assays was incubated (50 g protein/ml) with 7-ethoxyresorufin (0.025-0.4 M) with and without the selenazolidine (50 M). The cytochrome P450-catalyzed product (resorufin) formation rate was monitored (Ex, 544 nm; Fl, 612 nm) following the addition of NADPH (4 mM). Enzyme inhibition kinetics were analyzed using SigmaPlot Enzyme Kinetics Module 1.1 software (SPSS Inc., Chicago, IL).
Statistical analysis of data
Statistical analyses were performed using ANOVA, followed by Fisher's protected least significant difference multiple range test. Differences were considered significant at p values of <0.05.
Results and discussion
Cytotoxicity of selenazolidine-4-(R)-carboxylic acids
As a necessary prerequisite for mutagenic and antimutagenic activity determinations, the cytotoxicity of the SCAs towards S. typhimurium TA98 was investigated. In the liquid broth protocol, two compounds, 2-(2 -hydroxyphenyl)SCA and to a lesser extent the unsubstituted SCA, showed statistically significant cytotoxicity, but only when present at 100 M ( Table 1) . Several of the compounds showed an enhancement of viability at the lower concentrations (12.5-50 M), approximately 20% for 2-cyclohexyl-and 2-butylderivatives, but these were not statistically significant. In the colony/plate assay, significant increases in the number of colonies, ranging from 16 to 29% were seen at either 25 or 50 M for all compounds except SCA ( Table 2) . Whether the selenazolidines are providing additional selenium necessary for maximal growth or are acting through additional or alternative mechanisms is not known. The effect appears not confined to bacteria as in other studies, growth stimulation has also been observed for eukaryotic (murine and rat hepatoma) cells in culture [38] . In the colony/plate assay, no selenazolidine exhibited any cytotoxicity at the 25 and 50 M concentrations evaluated, an effect that would have resulted in a decrease in the number of colonies. Concentrations at or below 50 M were therefore selected as appropriate for antimutagenesis studies since the outcome would not likely be confounded by overt cytotoxicity concerns. However, antimutagenesis studies first required investigation of whether there is toxicity when selenazolidines and mutagens are present together, and also whether the selenazolidines alone have any mutagenic properties.
When bacteria were exposed to B[a]P, S9 mix and selenazolidines at 25 and 50 M, and evaluated for colony formation in the presence of adequate histidine, the result (Table 3 ) was similar to the effects seen with selenazolidines alone (Table 2 ). There was no diminution in the number of colonies (i.e., toxicity), and for most selenazolidines, there was a statistically significant increase in colony numbers in at least one of the plating densities of each of the duplicate experiments. When bacteria were exposed to acridine orange in the absence of S9 mix, and 10 and 25 M of each of the selenazolidines, the effects on colony numbers were quite similar to the above with one very noticeable exception (Table 4 ). In the presence of acridine orange, SCA at 25 M was toxic. This toxicity was not seen with either component alone at the concentrations employed, nor with co-exposure of bacteria to B[a]P and SCA, and therefore represents a detrimental combination unique to acridine orange and SCA. This toxicity precluded evaluation of any antimutagenic effect of SCA at 25 M on the mutagenicity of acridine orange.
Mutagenicity of selenazolidine-4-(R)-carboxylic acids
When examined for mutagenic activity at or below the non-toxic concentrations, none of the selenazolidines were mutagenic with or without aerobic incubation with the S9 mix (Table 5 ). Mutagenicity is defined as a doubling over the spontaneous or background number, together with selenazolidine concentration dependency, in the number of revertant colonies. As in the liquidmedium viability assay (Table 1) , both SCA and 2-(2 -hydroxyphenyl)SCA were toxic to the bacteria at 100 M and any mutagenic effects at this high concentration could not be evaluated.
Antimutagenicity of selenazolidine-4-(R)-carboxylic acids against B[a]P
Without exception, all the selenazolidines significantly reduced B[a]P mutagenicity ( Table 6) 
Effect of selenazolidine-4-(R)-carboxylic acid derivatives on CYP1A metabolism
When compounds are antimutagenic for mutagens that require bioactivation, one of the possible mechanisms of action is the inhibition of the bioactivation reaction. The antimutagenic effect of inorganic selenite towards B[a]P was attributed to this mechanism [5, 9] . Accordingly, the ability of the selenazolidines to affect S9 fraction 7-ethoxyresorufin O-deethylase activity, a reaction catalyzed by CYP1As was therefore investigated (Table 7) . The CYP1As are the enzymes largely responsible for B[a]P metabolism to 
Antimutagenicity of selenazolidine-4-(R)-carboxylic acid derivatives against acridine orange
Acridine orange does not require bioactivation to be mutagenic. Accordingly, selenazolidine antimutagenic activity was evaluated in the absence of S9 mix. The optimal non-toxic concentration of acridine orange for mutagenicity (100 M; data not shown) was used to evaluate the antimutagenic effect of the SCAs. All the SCAs reduced acridine orange mutagenicity and with the exception of SCA, in a concentration dependent manner (Table 8) (Tables 3 and 4) .
effect on the misreading of the modified DNA during replication.
Summary
All seven organoselenium compounds, SCA and six 2-substituted derivatives, were found to have antimutagenic activity. The antimutagenic activity was present for B[a]P, a carcinogen that requires oxidative bioactivation for mutagenicity, and for a DNA-intercalating mutagen requiring no activation (acridine orange). Antimutagenic activity against acridine orange was dependent on selenazolidine concentration. EC50 values ranged from 4.8 to 9.9 M. In contrast to effects with acridine orange, there was no apparent concentration dependency to antimutagenicity against B[a]P. Based on the ineffectiveness of six of seven selenazolidines to inhibit the B[a]P-activating CYP1A activity to any major extent at concentrations demonstrating antimutagenic activity, as well as the demonstrated greater antimutagenic activity towards acridine orange which requires no bioactivation, it is concluded that the selenazolidines do not exert their effect through this mechanism. At 25 M, the selenazolidine concentration tested in common for the two mutagens, the reduction in mutant frequency ranged from a mean low of 53.5% (2-cyclohexylSCA) to a mean high of 70.6% (2-methylSCA) for B[a]P. Against acridine orange, the range of reductions was approximately 25% higher, with a low of 78.7% (2-oxoSCA) and a high of 92.6% (2-cyclohexyl SCA) ( Table 9) There are few published studies on the antimutagenicity of organoselenium compounds with which to compare our observations. Seleno-amino acids were ineffective against 2-amino-3-methylimidazole[4,5]quinoline in vitro [22] . Antimutagenicity studies with organoselenium compounds synthesized and investigated by other research groups and known to possess chemoprevention activity against several mutagens/carcinogens in animal models would have considerable merit, and could provide the foundation for the utility of such testing in selecting lead compounds for long term and costly in vivo chemoprevention investigations. Results of the present selenazolidines, based on the antimutagenic activity of selenazolidines at non-toxic concentrations, suggest these compounds should be tested for chemopreventive properties in animal studies.
